111 Capital’s Sarepta Therapeutics SRPT Stock Holding History

111 Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,360	Closed	-$434K	–	674
2025 Q2	$434K	Buy	+25,360	New	+$1.08M	0.07%	279

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

111 Capital's SRPT Position: Q3 2025 in Review

111 Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 25,360 shares — an estimated $434K sold.

111 Capital first reported a position in SRPT in Q2 2025 and held it in 1 quarter. The position peaked at $434K in Q2 2025. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

111 Capital reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
111 Capital sold 25,360 Sarepta Therapeutics shares in Q3 2025, an estimated $434K.
111 Capital first reported a position in Sarepta Therapeutics in Q2 2025 and held it in 1 quarter.
111 Capital's Sarepta Therapeutics position peaked at $434K in Q2 2025.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.